Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
lasofoxifene cannabinoid receptor 2 small molecule NA drugbank Disease[MeSHID:D004194]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Bone structure of spine[MeSHID:D013131]
Vagina[MeSHID:D014621]
Fracture[MeSHID:D050723]
Malignant neoplasm of breast[MeSHID:D001943]
Risk Reduction[MeSHID:D040242]
Atrophic[MeSHID:D001284]
Vulva[MeSHID:D014844]
Virus Diseases[MeSHID:D014777]
Osteoporosis[MeSHID:D010024]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inverse agonist
lasofoxifene estrogen receptor NA Successful target TTD , DGIDB Disease[MeSHID:D004194]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Bone structure of spine[MeSHID:D013131]
Vagina[MeSHID:D014621]
Fracture[MeSHID:D050723]
Malignant neoplasm of breast[MeSHID:D001943]
Risk Reduction[MeSHID:D040242]
Atrophic[MeSHID:D001284]
Vulva[MeSHID:D014844]
Virus Diseases[MeSHID:D014777]
Osteoporosis[MeSHID:D010024]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.63 approved agonist
lasofoxifene estrogen receptor alpha small molecule NA drugbank , DGIDB Disease[MeSHID:D004194]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Bone structure of spine[MeSHID:D013131]
Vagina[MeSHID:D014621]
Fracture[MeSHID:D050723]
Malignant neoplasm of breast[MeSHID:D001943]
Risk Reduction[MeSHID:D040242]
Atrophic[MeSHID:D001284]
Vulva[MeSHID:D014844]
Virus Diseases[MeSHID:D014777]
Osteoporosis[MeSHID:D010024]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.63 approved,investigational antagonist,agonist,negative modulator
lasofoxifene estrogen receptor NA Successful target TTD , DGIDB Disease[MeSHID:D004194]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Bone structure of spine[MeSHID:D013131]
Vagina[MeSHID:D014621]
Fracture[MeSHID:D050723]
Malignant neoplasm of breast[MeSHID:D001943]
Risk Reduction[MeSHID:D040242]
Atrophic[MeSHID:D001284]
Vulva[MeSHID:D014844]
Virus Diseases[MeSHID:D014777]
Osteoporosis[MeSHID:D010024]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.63 approved unknown
lasofoxifene estrogen receptor beta small molecule NA drugbank , DGIDB Disease[MeSHID:D004194]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Bone structure of spine[MeSHID:D013131]
Vagina[MeSHID:D014621]
Fracture[MeSHID:D050723]
Malignant neoplasm of breast[MeSHID:D001943]
Risk Reduction[MeSHID:D040242]
Atrophic[MeSHID:D001284]
Vulva[MeSHID:D014844]
Virus Diseases[MeSHID:D014777]
Osteoporosis[MeSHID:D010024]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.92 approved,investigational agonist
click here to return to the previous page